Kyeong Ho Yun
Overview
Explore the profile of Kyeong Ho Yun including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
1247
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
51.
Lee S, Cho J, Kim B, Yun K, Suh Y, Cho Y, et al.
JACC Cardiovasc Interv
. 2021 Feb;
14(4):431-440.
PMID: 33602439
Objectives: The aim of this study was to assess whether the effects of ticagrelor monotherapy after 3-month dual-antiplatelet therapy (DAPT) are consistent among patients presenting with ST-segment elevation myocardial infarction...
52.
Yun K, Cho J, Yul Lee S, Rhee S, Kim B, Hong M, et al.
Front Pharmacol
. 2021 Feb;
11:620906.
PMID: 33519487
: Ticagrelor monotherapy after 3 months dual antiplatelet therapy (DAPT) with aspirin and ticagrelor can reduce bleeding without increasing ischemic events after percutaneous coronary intervention (PCI). However, the impact of...
53.
Byoun J, Cho J, Yun K, Rhee S, Yu S, Oh S
Int Heart J
. 2021 Jan;
62(1):207-210.
PMID: 33455992
Mid-aortic syndrome (MAS) is a rare condition characterized by stenosis of the distal thoracic and/or abdominal aorta. Williams-Beuren syndrome (WBS) is a relatively rare cause of MAS. We report a...
54.
Yun K, Lee S, Cho B, Jang W, Song Y, Oh J, et al.
J Am Heart Assoc
. 2020 Dec;
10(1):e018366.
PMID: 33345567
Background This study sought to investigate the safety of 3-month dual antiplatelet therapy (DAPT) in patients receiving ultrathin sirolimus-eluting stents with biodegradable polymer (Orsiro). Methods and Results The SMART-CHOICE (Smart...
55.
Kim B, Hong S, Cho Y, Yun K, Kim Y, Suh Y, et al.
JAMA
. 2020 Jun;
323(23):2407-2416.
PMID: 32543684
Importance: Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was evaluated as a bleeding reduction strategy. However, the strategy of ticagrelor monotherapy has not been exclusively evaluated in patients with...
56.
57.
Yun K, Cho J, Rhee S, Oh S
Korean Circ J
. 2019 Jul;
49(11):1052-1061.
PMID: 31347319
Background And Objectives: The degree of antiplatelet response to P2Y12 inhibitors has been associated with clinical outcomes. The aim of this study was to test the variability of platelet reactivity...
58.
Hahn J, Song Y, Oh J, Chun W, Park Y, Jang W, et al.
JAMA
. 2019 Jun;
321(24):2428-2437.
PMID: 31237645
Importance: Data on P2Y12 inhibitor monotherapy after short-duration dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention are limited. Objective: To determine whether P2Y12 inhibitor monotherapy after 3 months...
59.
Kim Y, Jeong M, Ahn Y, Kim J, Hong Y, Sim D, et al.
Am J Cardiol
. 2018 Jul;
122(3):365-373.
PMID: 30041888
Limited information exists about characteristics of patients with acute myocardial infarction (AMI) in Asia. We examined trends in interventional treatment and clinical outcomes for AMI from the Korea Acute Myocardial...
60.
Kim Y, Oh S, Jeong M, Ahn Y, Kim J, Hong Y, et al.
Cardiol J
. 2018 May;
26(5):469-476.
PMID: 29745969
Background: There are few studies which compare the efficacy and safety of the Resolute Onyx zotarolimus-eluting stent (O-ZES) and everolimus-eluting stent (EES) in patients with acute myocardial infarction (AMI). Therefore,...